Improving psychiatric drug therapy. A matter of dosage and choice.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000098:blood supply; D003704:Dementia / Q000139:chemically induced; D003863:Depression / Q000188:drug therapy / Q000628:therapy; D004359:Drug Therapy, Combination; D004565:Electroconvulsive Therapy; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy*; D008698:Mesylates / Q000627:therapeutic use; D009069:Movement Disorders / Q000139:chemically induced; D010208:Papaverine / Q000627:therapeutic use; D010433:Pentylenetetrazole / Q000627:therapeutic use; D013881:Thioridazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D006993:Hypnotics and Sedatives; D008698:Mesylates; D014149:Tranquilizing Agents; D010208:Papaverine; D013881:Thioridazine; D010433:Pentylenetetrazole